Group 1 - The core point of the news is that 博拓生物's stock price has decreased by 5.01%, currently trading at 39.05 CNY per share, with a total market capitalization of 58.31 billion CNY [1] - 博拓生物, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 92.91% of its revenue coming from diagnostic reagent products [1] - The trading volume for 博拓生物 reached 2.27 billion CNY, with a turnover rate of 3.76% [1] Group 2 - From the perspective of major shareholders, 广发价值核心混合A (010377) holds 2.56% of 博拓生物's circulating shares, with a current floating loss of approximately 563.17 million CNY [2] - The fund has achieved a return of 68.54% year-to-date and 114.67% over the past year, ranking 147 out of 8194 and 129 out of 7963 respectively [2] - The fund manager, 吴远怡, has been in charge for 4 years and 333 days, with a total asset scale of 204.78 billion CNY [3] Group 3 - In the second quarter, 广发价值核心混合A (010377) held 423.6 million shares of 博拓生物, representing 2.75% of the fund's net value, making it the eighth largest holding [4] - The current floating loss for the fund regarding 博拓生物 is estimated at 872.62 million CNY [4]
博拓生物股价跌5.01%,广发基金旗下1只基金重仓,持有423.6万股浮亏损失872.62万元